Novel Phenoxazinones as potent agonist of PPAR-α: design ...
Erythropoietin receptor agonist for anaemia in dialysis patients
1
Inpharma 1584 - 21 Apr 2007 ■ An erythropoietin receptor agonist [Hematide] * shows promise for the treatment of anaemia in patients receiving dialysis, according to the results of a phase II trial presented at the National Kidney Foundation Spring Clinical Meeting. In this open-label, multiple-dose trial, 165 such patients who had been treated with three-times-weekly epoetin-α were switched to receive once monthly hematide at an appropriate dose. For 90 patients completing six months of therapy, the mean reticulocyte count increased following each dose of hematide. In addition, the mean haemoglobin level was maintained within ± 1 g/dL of the baseline value (11.5 g/dL), at the end of treatment. * Affymax, Nektar Therapeutics; phase II in the US, the UK and Europe for anaemia Affymax Inc. Affymax(R) Announces Results From Phase 2 Clinical Trial of Hematide™ for the Treatment of Anemia in Dialysis Patients. Media Release : 13 Apr 2007. Available from: URL: http://www.affymax.com 809074399 1 Inpharma 21 Apr 2007 No. 1584 1173-8324/10/1584-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
-
date post
09-Dec-2016 -
Category
Documents
-
view
214 -
download
1
Transcript of Erythropoietin receptor agonist for anaemia in dialysis patients
Inpharma 1584 - 21 Apr 2007
■ An erythropoietin receptor agonist [Hematide]*shows promise for the treatment of anaemia inpatients receiving dialysis, according to the results of aphase II trial presented at the National KidneyFoundation Spring Clinical Meeting. In this open-label,multiple-dose trial, 165 such patients who had beentreated with three-times-weekly epoetin-α wereswitched to receive once monthly hematide at anappropriate dose. For 90 patients completing sixmonths of therapy, the mean reticulocyte countincreased following each dose of hematide. Inaddition, the mean haemoglobin level was maintainedwithin ± 1 g/dL of the baseline value (11.5 g/dL), at theend of treatment.* Affymax, Nektar Therapeutics; phase II in the US, the UK andEurope for anaemia
Affymax Inc. Affymax(R) Announces Results From Phase 2 Clinical Trial ofHematide™ for the Treatment of Anemia in Dialysis Patients. Media Release :13 Apr 2007. Available from: URL: http://www.affymax.com 809074399
1
Inpharma 21 Apr 2007 No. 15841173-8324/10/1584-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
